Biotech IV Monitor

IBRX — ImmunityBio Inc.

$7.4B market cap · 9 upcoming readouts tracked

Clinical trial readout dates for ImmunityBio Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.

Next readoutMarch 2027in ~4 months
Upcoming readouts91 Phase 3
Market cap$7.4B
Cash & investments$334M~2 quarters at last loss rate
Recent 8-K filings2latest 2026-11-09

Upcoming readouts

Phase 2 Anktiva
Long COVID; Long COVID Syndrome · NCT07123727
March 2027
Recruiting
Phase 2 Gemcitabine
Platinum-resistant Ovarian Cancer · NCT06710288
May 2027
Recruiting
Phase 2 CD19 t-haNK- IV Administration
Relapsed B-Cell Non Hodgkin Lymphoma · NCT07125872
May 2027
Recruiting
Phase 2 Nogapendekin alfa inbakicept (NAI)
Sepsis; Septic Shock · NCT07578558
August 2027
Not Yet Recruiting
Phase 2 CD19 t-haNK- IV Administration
Relapsed B-Cell Non-Hodgkin Lymphoma · NCT07477366
December 2027
Not Yet Recruiting
Phase 1/2 Intravesical Recombinant Mycobacterium (rMBCG)
NMIBC · NCT06800963
February 2028
Recruiting
Phase 2 Nogapendekin alfa inbakicept (NAI)
Sepsis · NCT07783789
May 2028
Not Yet Recruiting
Phase 3 N-803
NSCLC Stage IV · NCT06745908
September 2028
Recruiting
Phase 2 N-803 + Pembrolizumab
Non-Small Cell Lung Cancer; Small Cell Lung Cancer · NCT03228667
August 2029
Ongoing

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 2 N-803 and BCG
Non-muscle Invasive Bladder Cancer (NMIBC) · NCT06829823
November 2026
Not Yet Recruiting

Cash position

ImmunityBio Inc. reported $334M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $185M; at that rate the cash would last about 2 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-09
8-K Reg FD Disclosure — often a data announcement2026-11-09

Companies working on similar indications

Discussion

No messages yet. If you follow IBRX, you can start the conversation.
Track IBRX in real time
See live implied volatility for IBRX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on IBRX
Contact — questions or corrections about IBRX: dukeupt@gmail.com